NHS England updates CDF List
NHS England updates CDF List
NHS England has updated the Cancer Drugs Fund List. The latest version (v1.399) was uploaded to the NHS England Website on Thursday 21, May 2026.
The following changes have been introduced:
Tisotumab vedotin (TISV1)
For treating recurrent or metastatic cervical cancer that has progressed on or after systemic treatment where the following criteria have been met
Recommended for routine commissioning, receiving CDF interim funding
Durvalumab with chemotherapy (DUR9)
For neoadjuvant and adjuvant treatment then alone for adjuvant treatment of resectable gastric or gastro-oesophageal junction adenocarcinoma where the following criteria have been met
Treatment criteria (#4) updated
Pembrolizumab (PEMB8)
Pembrolizumab in combination with pemetrexed- and platinum-based chemotherapy for the first line treatment of PD-L1 positive or negative locally advanced or metastatic non-squamous non-small cell lung cancer where all the following criteria are met:
Treatment criterion (#1 and 6) updated
Pembrolizumab in combination with or nab-paclitaxel (PEMB18)
The treatment of previously untreated locally advanced unresectable or metastatic triple negative breast cancer patients with PD-L1 expression test results of immune cell (IC) <1% and a combined positive score (CPS) of 10 or more where the following criteria have been met
Treatment criterion (#1, 9 and 14) updated; Treatment criterion (#2 and 15) removed
Pembrolizumab monotherapy (PEMB31)
Pembrolizumab MONOTHERAPY for adjuvant treatment after complete tumour resection in adult patients with UICC/AJCC 8th edition stage IIA or IIB or IIIA or N2 only IIIB non-small cell lung cancer and whose disease has not progressed on recently completed adjuvant platinum-based chemotherapy where the following criteria have been met
Treatment criterion (#1, 12 and 16) updated; Treatment criterion (#2, 17 and 18) removed